Table of Content


Winter 2014, Vol. 22 No. 4

Hong Kong J. Dermatol. Venereol. (2014) 22, 169-173

Original Article

Hydroxyurea in the treatment of severe psoriasis: a retrospective review from Singapore


SY Chuah 蔡賽儀, HHB Oon 溫惠文, CTS Theng 唐添成, WS Chong 張維盛, JY Pan 潘君毅


Introduction: Hydroxyurea is a third-line systemic agent for the treatment of psoriasis in Singapore. We aimed to evaluate the therapeutic efficacy and safety of hydroxyurea. Methods: This was a retrospective review of all psoriasis patients started on hydroxyurea at a tertiary dermatology referral centre in the National Skin Centre, Singapore from 2004-2011. Results: Forty-seven patients were included. The mean body surface area (BSA) before starting hydroxyurea was 48% (2-80%). The best mean BSA achieved was 16.5% (4-60%). Clinical improvement was reported by physicians in 32% (n=15) of the patients and no improvement in 68% (n=32) of patients. From the patient's perspective; 4% (n=2) reported an excellent effect and 32% (n=15) good effect but 42% (n=20) had no effect and 21% (n=10) had worsening of their psoriasis. The adverse effects were minimal: 34% (n=16) no adverse effects; 53% (n=25) macrocytosis and mild megaloblastic anaemia; 8.5% (n=4) thrombocytopaenia; 6% (n=3) leucopaenia and 6% (n=3) cutaneous reactions. Conclusion: Our study suggests that hydroxyurea is relatively safe and effective in some patients and can be considered as a useful alternative for those who are unable to continue other systemic agents due to adverse events or cost.


Keywords: Hydroxyurea, management, psoriasis

關鍵詞: 羥基脲、管理、銀屑病